Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937307 | 1.00 | LMNA (0.34) | LMNAUSP2SLCO1B1PGDPDE4A | |
| SCHEMBL768930 | 0.83 | LMNA (0.32) | LMNAUSP2SLCO1B1PDE4A | |
| SCHEMBL14639283 | 0.83 | LMNA (0.32) | LMNAUSP2SLCO1B1PDE4A | |
| SCHEMBL14639329 | 0.83 | LMNA (0.32) | LMNAUSP2SLCO1B1PDE4A | |
| SCHEMBL8497603 | 0.77 | USP2 (0.41) | LMNAUSP2SLCO1B1PDE4AL3MBTL1 | |
| Phosphoric Acid SCHEMBL25406533 | 0.77 | USP2 (0.37) | LMNAUSP2SLCO1B1PGDPDE4A | |
| Phosphoric Acid SCHEMBL17728280 | 0.77 | USP2 (0.37) | LMNAUSP2SLCO1B1PGDPDE4A | |
| Phosphoric Acid SCHEMBL17728278 | 0.77 | USP2 (0.37) | LMNAUSP2SLCO1B1PGDPDE4A | |
| SCHEMBL16934820 | 0.76 | — | — | |
| SCHEMBL8615080 | 0.76 | SMPD1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618269-B2 | Glycorandomization and production of novel novobiocin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-20040259228-A1 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LMNA 3563/4885USP2 3688/4885SLCO1B1 1481/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | LMNA 2801/4885USP2 3575/4885SLCO1B1 1944/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LMNA 3817/4885USP2 3573/4885SLCO1B1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.